GlassScriptPhysician profile
John Joseph Allan
NPI 1235121997
$11,570.07
in general payments reported to CMS, 2019-2025
41 companies · $1,810 in 2025
The $1,810 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $1,533 · 2021: $1,519 · 2022: $1,378 · 2023: $1,269 · 2024: $2,109 · 2025: $1,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,953 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,952.74 |
| Education | $236.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $2,181.46 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Janssen Pharmaceuticals, INC | $1,082.79 | 2019-2024 | Xarelto, Uptravi |
| Novartis Pharmaceuticals Corporation | $964.17 | 2019-2025 | |
| Pfizer INC. | $943.76 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $665.14 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Abbott Laboratories | $617.43 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Bayer Healthcare Pharmaceuticals INC. | $535.37 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $533.84 | 2022-2025 | Verquvo, Winrevair |
| Sanofi-Aventis U.S. LLC | $523.09 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.39 | 2019-2025 | Jardiance |
| Amgen INC. | $464.22 | 2019-2023 | Repatha |
| Novo Nordisk INC | $343.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $246.53 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $164.04 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.90 | 2019-2025 | Lifevest |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $143.91 | 2019 | |
| Alnylam Pharmaceuticals INC. | $129.77 | 2020-2025 | |
| Baxter Healthcare | $123.33 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $123.21 | 2024 | Arcalyst |
| United Therapeutics Corporation | $118.71 | 2019-2025 | Tyvaso |
| Medtronic, INC. | $118.09 | 2021-2024 | Mycarelink |
| Arbor Pharmaceuticals, INC. | $109.72 | 2019-2021 | |
| Bridgebio Pharma, INC. | $99.39 | 2025 | Attruby |
| Cvrx, INC. | $89.19 | 2024-2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $84.14 | 2021-2025 | Nexletol |
| Edwards Lifesciences Corporation | $74.44 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $68.88 | 2024-2025 | |
| Ge Healthcare | $46.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $45.96 | 2019-2023 | Evkeeza |
| Biotronik INC. | $43.42 | 2025 | Biomonitor, Acticor 7 Vr-T Dx |
| Medtronic Vascular, INC. | $42.85 | 2019-2020 | |
| Bardy Diagnostics, INC. | $36.00 | 2019-2020 | |
| Lundbeck LLC | $33.48 | 2020-2021 | |
| Irhythm Technologies, INC. | $32.83 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $23.40 | 2019 | |
| Lilly USA, LLC | $18.00 | 2025 | Zepbound |
| Mannkind Corporation | $16.30 | 2025 | |
| Argon Medical Devices, INC. | $15.46 | 2023 | Cleaner |
| Portola Pharmaceuticals, LLC | $14.41 | 2020 | |
| Altathera Pharmaceuticals LLC | $14.39 | 2025 | Sotalol Hydrochloride |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Allan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.